Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Dec;85(12):1928–1936. doi: 10.1054/bjoc.2001.2179

Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer

V J Gnanapragasam 1, H Y Leung 1, A S Pulimood 1, D E Neal 1, C N Robson 1
PMCID: PMC2364015  PMID: 11747336

Abstract

RAC 3, one of the p160 family of co-activators is known to enhance the transcriptional activity of a number of steroid receptors. As co-activators are also known to enhance androgen receptor (AR) activity, we investigated the role of RAC 3 in the context of prostate cancer. In prostate cancer cell lines, we found variable levels of the RAC 3 protein with highest expression seen in AR-positive LNCaP cells, moderate expression in AR-negative PC 3 cells and low-level expression in AR-negative DU 145 cells. Immuno-precipitation studies showed that endogenous RAC 3 interacted with the AR in vivo and transfection assays confirmed that RAC 3 enhanced AR transcriptional activity. In clinical prostate tissue, we found strong RAC 3 mRNA expression and immuno-histochemistry demonstrated that in benign tissue, the protein was expressed predominantly in luminal cells, while in primary malignant epithelium it was more homogeneously expressed. In a series of 37 patients, the levels of RAC 3 expression correlated significantly with tumour grade (P = 0.01) and stage of disease (P = 0.03) but not with serum PSA levels. In addition moderate or high RAC 3 expression was associated with poorer disease-specific survival (P = 0.03). We conclude that RAC 3 is an important co-activator of the AR in the prostate and may have an important role in the progression of prostate cancer. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: RAC 3, co-activator, androgen receptor, prostate cancer, survival outcome

Full Text

The Full Text of this article is available as a PDF (142.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarnisalo P., Palvimo J. J., Jänne O. A. CREB-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2122–2127. doi: 10.1073/pnas.95.5.2122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alen P., Claessens F., Schoenmakers E., Swinnen J. V., Verhoeven G., Rombauts W., Peeters B. Interaction of the putative androgen receptor-specific coactivator ARA70/ELE1alpha with multiple steroid receptors and identification of an internally deleted ELE1beta isoform. Mol Endocrinol. 1999 Jan;13(1):117–128. doi: 10.1210/mend.13.1.0214. [DOI] [PubMed] [Google Scholar]
  3. Anzick S. L., Kononen J., Walker R. L., Azorsa D. O., Tanner M. M., Guan X. Y., Sauter G., Kallioniemi O. P., Trent J. M., Meltzer P. S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997 Aug 15;277(5328):965–968. doi: 10.1126/science.277.5328.965. [DOI] [PubMed] [Google Scholar]
  4. Azorsa D. O., Meltzer P. S. Production and characterization of monoclonal antibodies to the steroid receptor coactivator AIB1. Hybridoma. 1999 Jun;18(3):281–287. doi: 10.1089/027245799315943. [DOI] [PubMed] [Google Scholar]
  5. Bautista S., Vallès H., Walker R. L., Anzick S., Zeillinger R., Meltzer P., Theillet C. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin Cancer Res. 1998 Dec;4(12):2925–2929. [PubMed] [Google Scholar]
  6. Berns E. M., van Staveren I. L., Klijn J. G., Foekens J. A. Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer. Breast Cancer Res Treat. 1998 Mar;48(1):87–92. doi: 10.1023/a:1005903226483. [DOI] [PubMed] [Google Scholar]
  7. Bonkhoff H., Fixemer T., Hunsicker I., Remberger K. Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol. 1999 Aug;155(2):641–647. doi: 10.1016/S0002-9440(10)65160-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Borrow J., Stanton V. P., Jr, Andresen J. M., Becher R., Behm F. G., Chaganti R. S., Civin C. I., Disteche C., Dubé I., Frischauf A. M. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet. 1996 Sep;14(1):33–41. doi: 10.1038/ng0996-33. [DOI] [PubMed] [Google Scholar]
  9. Brady M. E., Ozanne D. M., Gaughan L., Waite I., Cook S., Neal D. E., Robson C. N. Tip60 is a nuclear hormone receptor coactivator. J Biol Chem. 1999 Jun 18;274(25):17599–17604. doi: 10.1074/jbc.274.25.17599. [DOI] [PubMed] [Google Scholar]
  10. Cher M. L., Bova G. S., Moore D. H., Small E. J., Carroll P. R., Pin S. S., Epstein J. I., Isaacs W. B., Jensen R. H. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 1996 Jul 1;56(13):3091–3102. [PubMed] [Google Scholar]
  11. Culig Z., Klocker H., Eberle J., Kaspar F., Hobisch A., Cronauer M. V., Bartsch G. DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction. Prostate. 1993;22(1):11–22. doi: 10.1002/pros.2990220103. [DOI] [PubMed] [Google Scholar]
  12. Font de Mora J., Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol. 2000 Jul;20(14):5041–5047. doi: 10.1128/mcb.20.14.5041-5047.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Fujimoto N., Mizokami A., Harada S., Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology. 2001 Aug;58(2):289–294. doi: 10.1016/s0090-4295(01)01117-7. [DOI] [PubMed] [Google Scholar]
  14. Ghadimi B. M., Schröck E., Walker R. L., Wangsa D., Jauho A., Meltzer P. S., Ried T. Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. Am J Pathol. 1999 Feb;154(2):525–536. doi: 10.1016/S0002-9440(10)65298-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hassig C. A., Schreiber S. L. Nuclear histone acetylases and deacetylases and transcriptional regulation: HATs off to HDACs. Curr Opin Chem Biol. 1997 Oct;1(3):300–308. doi: 10.1016/s1367-5931(97)80066-x. [DOI] [PubMed] [Google Scholar]
  16. Hobisch A., Culig Z., Radmayr C., Bartsch G., Klocker H., Hittmair A. Androgen receptor status of lymph node metastases from prostate cancer. Prostate. 1996 Feb;28(2):129–135. doi: 10.1002/(SICI)1097-0045(199602)28:2<129::AID-PROS9>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  17. Horwitz K. B., Jackson T. A., Bain D. L., Richer J. K., Takimoto G. S., Tung L. Nuclear receptor coactivators and corepressors. Mol Endocrinol. 1996 Oct;10(10):1167–1177. doi: 10.1210/mend.10.10.9121485. [DOI] [PubMed] [Google Scholar]
  18. Kang H. Y., Yeh S., Fujimoto N., Chang C. Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor. J Biol Chem. 1999 Mar 26;274(13):8570–8576. doi: 10.1074/jbc.274.13.8570. [DOI] [PubMed] [Google Scholar]
  19. Koivisto P., Kononen J., Palmberg C., Tammela T., Hyytinen E., Isola J., Trapman J., Cleutjens K., Noordzij A., Visakorpi T. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997 Jan 15;57(2):314–319. [PubMed] [Google Scholar]
  20. Lau K. M., LaSpina M., Long J., Ho S. M. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 2000 Jun 15;60(12):3175–3182. [PubMed] [Google Scholar]
  21. Li H., Chen J. D. The receptor-associated coactivator 3 activates transcription through CREB-binding protein recruitment and autoregulation. J Biol Chem. 1998 Mar 6;273(10):5948–5954. doi: 10.1074/jbc.273.10.5948. [DOI] [PubMed] [Google Scholar]
  22. Li H., Gomes P. J., Chen J. D. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8479–8484. doi: 10.1073/pnas.94.16.8479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Meyer M. E., Gronemeyer H., Turcotte B., Bocquel M. T., Tasset D., Chambon P. Steroid hormone receptors compete for factors that mediate their enhancer function. Cell. 1989 May 5;57(3):433–442. doi: 10.1016/0092-8674(89)90918-5. [DOI] [PubMed] [Google Scholar]
  24. Meyer M. E., Quirin-Stricker C., Lerouge T., Bocquel M. T., Gronemeyer H. A limiting factor mediates the differential activation of promoters by the human progesterone receptor isoforms. J Biol Chem. 1992 May 25;267(15):10882–10887. [PubMed] [Google Scholar]
  25. Miyamoto H., Yeh S., Wilding G., Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7379–7384. doi: 10.1073/pnas.95.13.7379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Müller J. M., Isele U., Metzger E., Rempel A., Moser M., Pscherer A., Breyer T., Holubarsch C., Buettner R., Schüle R. FHL2, a novel tissue-specific coactivator of the androgen receptor. EMBO J. 2000 Feb 1;19(3):359–369. doi: 10.1093/emboj/19.3.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Nessler-Menardi C., Jotova I., Culig Z., Eder I. E., Putz T., Bartsch G., Klocker H. Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models. Prostate. 2000 Oct 1;45(2):124–131. doi: 10.1002/1097-0045(20001001)45:2<124::aid-pros6>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  28. Peterziel H., Mink S., Schonert A., Becker M., Klocker H., Cato A. C. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene. 1999 Nov 4;18(46):6322–6329. doi: 10.1038/sj.onc.1203032. [DOI] [PubMed] [Google Scholar]
  29. Sadi M. V., Walsh P. C., Barrack E. R. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer. 1991 Jun 15;67(12):3057–3064. doi: 10.1002/1097-0142(19910615)67:12<3057::aid-cncr2820671221>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  30. Sakakura C., Hagiwara A., Yasuoka R., Fujita Y., Nakanishi M., Masuda K., Kimura A., Nakamura Y., Inazawa J., Abe T. Amplification and over-expression of the AIB1 nuclear receptor co-activator gene in primary gastric cancers. Int J Cancer. 2000 May 20;89(3):217–223. [PubMed] [Google Scholar]
  31. Scolnick D. M., Chehab N. H., Stavridi E. S., Lien M. C., Caruso L., Moran E., Berger S. L., Halazonetis T. D. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 1997 Sep 1;57(17):3693–3696. [PubMed] [Google Scholar]
  32. Tan J. A., Hall S. H., Petrusz P., French F. S. Thyroid receptor activator molecule, TRAM-1, is an androgen receptor coactivator. Endocrinology. 2000 Sep;141(9):3440–3450. doi: 10.1210/endo.141.9.7680. [DOI] [PubMed] [Google Scholar]
  33. Tikkanen M. K., Carter D. J., Harris A. M., Le H. M., Azorsa D. O., Meltzer P. S., Murdoch F. E. Endogenously expressed estrogen receptor and coactivator AIB1 interact in MCF-7 human breast cancer cells. Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12536–12540. doi: 10.1073/pnas.220427297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Wadgaonkar R., Collins T. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression. J Biol Chem. 1999 May 14;274(20):13760–13767. doi: 10.1074/jbc.274.20.13760. [DOI] [PubMed] [Google Scholar]
  35. Wadgaonkar R., Phelps K. M., Haque Z., Williams A. J., Silverman E. S., Collins T. CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. J Biol Chem. 1999 Jan 22;274(4):1879–1882. doi: 10.1074/jbc.274.4.1879. [DOI] [PubMed] [Google Scholar]
  36. Wainstein M. A., He F., Robinson D., Kung H. J., Schwartz S., Giaconia J. M., Edgehouse N. L., Pretlow T. P., Bodner D. R., Kursh E. D. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res. 1994 Dec 1;54(23):6049–6052. [PubMed] [Google Scholar]
  37. Werbajh S., Nojek I., Lanz R., Costas M. A. RAC-3 is a NF-kappa B coactivator. FEBS Lett. 2000 Nov 24;485(2-3):195–199. doi: 10.1016/s0014-5793(00)02223-7. [DOI] [PubMed] [Google Scholar]
  38. Wilson C. M., McPhaul M. J. A and B forms of the androgen receptor are present in human genital skin fibroblasts. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1234–1238. doi: 10.1073/pnas.91.4.1234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Xu J., Liao L., Ning G., Yoshida-Komiya H., Deng C., O'Malley B. W. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6379–6384. doi: 10.1073/pnas.120166297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Xu J., Qiu Y., DeMayo F. J., Tsai S. Y., Tsai M. J., O'Malley B. W. Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science. 1998 Mar 20;279(5358):1922–1925. doi: 10.1126/science.279.5358.1922. [DOI] [PubMed] [Google Scholar]
  41. Yeh S., Chang C. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. Proc Natl Acad Sci U S A. 1996 May 28;93(11):5517–5521. doi: 10.1073/pnas.93.11.5517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Yeh S., Miyamoto H., Shima H., Chang C. From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc Natl Acad Sci U S A. 1998 May 12;95(10):5527–5532. doi: 10.1073/pnas.95.10.5527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. van der Kwast T. H., Schalken J., Ruizeveld de Winter J. A., van Vroonhoven C. C., Mulder E., Boersma W., Trapman J. Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer. 1991 May 10;48(2):189–193. doi: 10.1002/ijc.2910480206. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES